{"id":"NCT02065622","sponsor":"AbbVie","briefTitle":"Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis","officialTitle":"A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03-27","primaryCompletion":"2019-09-05","completion":"2019-11-11","firstPosted":"2014-02-19","resultsPosted":"2020-10-08","lastUpdate":"2020-11-23"},"enrollment":952,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis (UC)"],"interventions":[{"type":"DRUG","name":"Adalimumab","otherNames":["Humira"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Induction (Main Study + Japan Sub-study): I-SD","type":"EXPERIMENTAL"},{"label":"Induction (Main Study + Japan Sub-study): I-HD","type":"EXPERIMENTAL"},{"label":"Maintenance (Main Study + Japan Sub-study): M-SD","type":"EXPERIMENTAL"},{"label":"Maintenance (Main Study + Japan Sub-study): M-HD","type":"EXPERIMENTAL"},{"label":"Maintenance (Main Study): TDM Regimen","type":"EXPERIMENTAL"}],"summary":"To evaluate safety and efficacy of two adalimumab dosing regimens for induction and maintenance (standard and higher dosing) in achieving clinical remission in subjects with moderately to severely active ulcerative colitis.","primaryOutcome":{"measure":"Induction Period Primary Endpoint: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 8","timeFrame":"Week 8","effectByArm":[{"arm":"Induction (Main Study): I-SD","deltaMin":10.9,"sd":null},{"arm":"Induction (Main Study): I-HD","deltaMin":13.3,"sd":null},{"arm":"Induction (Main Study + Japan Sub-study): I-SD","deltaMin":11.6,"sd":null},{"arm":"Induction (Main Study + Japan Sub-study): I-HD","deltaMin":13.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.269"},{"comp":"OG000 vs OG001","p":"0.447"},{"comp":"OG002 vs OG003","p":"0.301"},{"comp":"OG002 vs OG003","p":"0.502"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":173,"countries":["United States","Austria","Belgium","Canada","Czechia","Denmark","France","Germany","Hungary","Israel","Italy","Japan","Netherlands","Poland","Romania","Slovakia","Spain","Switzerland","Ukraine","United Kingdom"]},"refs":{"pmids":["39162746","37801628","36905528","34402466"],"seeAlso":["http://rxabbvie.com/"]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":379},"commonTop":["COLITIS ULCERATIVE","NASOPHARYNGITIS","HEADACHE","ARTHRALGIA","UPPER RESPIRATORY TRACT INFECTION"]}}